Suppr超能文献

P53和HSP70在慢性肝炎、肝硬化及早期和晚期肝细胞癌组织中的表达及其在肝细胞癌中的诊断价值:一项免疫组织化学研究

Expression of P53 and HSP70 in Chronic Hepatitis, Liver Cirrhosis, and Early and Advanced Hepatocellular Carcinoma Tissues and Their Diagnostic Value in Hepatocellular Carcinoma: An Immunohistochemical Study.

作者信息

Wang Zhi, Gou Wenbin, Liu Ming, Sang Wei, Chu Hui, Zhang Wei

机构信息

Department of Pathology, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang, China (mainland).

出版信息

Med Sci Monit. 2015 Oct 23;21:3209-15. doi: 10.12659/msm.895592.

Abstract

BACKGROUND

Tumor protein (P53) and heat shock protein 70 (HSP70) play key roles in chronic liver diseases. This study aimed to characterize P53 and HSP70 expression in chronic hepatitis (CH), liver cirrhosis (LC), early and advanced HCC, and to analyze their diagnostic value in hepatocellular carcinoma (HCC).

MATERIAL AND METHODS

Immunohistochemical staining was conducted to evaluate the expression of P53 and HSP70 in 200 human liver tissue specimens, with advanced HCC (n=80), early HCC (n=30), CH (n=30), LC (n=30), and Controls (n=30).

RESULTS

P53 expression levels were lower in LC than those of HCC, but remained on par with those of CH and Controls. HSP70 expression levels were higher in HCC than those of LC, CH, and Controls. The sensitivity and specificity for HCC diagnosis were: 50.9% and 98.9% for P53, and 78.2 and 77.8% for HSP70, respectively. The sensitivity and specificity of different combinations were: 95.5% and 85.5% with either P53 or HSP70 being positive, and 33.6% and 98.9% if both were positive. Among the differentiation stages marked low, intermediate, and high in HCC, the P53 positive rate was higher in the low than in the intermediate, which was higher than that in the high. HSP70 positive rate was higher in the low and the intermediate than in the high, but no obvious changes were found between the low and the intermediate.

CONCLUSIONS

P53 and HSP70 could be potential biomarkers for HCC diagnosis, and proper combinations of these 2 markers could improve diagnostic accuracy.

摘要

背景

肿瘤蛋白(P53)和热休克蛋白70(HSP70)在慢性肝病中起关键作用。本研究旨在表征P53和HSP70在慢性肝炎(CH)、肝硬化(LC)、早期和晚期肝癌中的表达情况,并分析它们在肝细胞癌(HCC)中的诊断价值。

材料与方法

采用免疫组织化学染色法评估200例人类肝组织标本中P53和HSP70的表达,其中包括晚期肝癌(n = 80)、早期肝癌(n = 30)、慢性肝炎(n = 30)、肝硬化(n = 30)以及对照组(n = 30)。

结果

LC中P53表达水平低于HCC,但与CH和对照组相当。HCC中HSP70表达水平高于LC、CH和对照组。HCC诊断的敏感性和特异性分别为:P53为50.9%和98.9%,HSP70为78.2%和77.8%。不同组合的敏感性和特异性分别为:P53或HSP70阳性时为95.5%和85.5%,两者均阳性时为33.6%和98.9%。在HCC的低、中、高分化阶段中,低分化阶段的P53阳性率高于中分化阶段,中分化阶段高于高分化阶段。低分化和中分化阶段的HSP70阳性率高于高分化阶段,但低分化和中分化阶段之间无明显变化。

结论

P53和HSP70可能是HCC诊断的潜在生物标志物,这两种标志物的适当组合可提高诊断准确性。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b18a/4622226/6c7a5c58dae2/medscimonit-21-3209-g001.jpg

相似文献

5
Decreased expression of hsa_circ_0003570 in hepatocellular carcinoma and its clinical significance.
J Clin Lab Anal. 2018 Feb;32(2). doi: 10.1002/jcla.22239. Epub 2017 May 11.
7
Cyclooxygenase-2 and vascular endothelial growth factor in chronic hepatitis, cirrhosis and hepatocellular carcinoma.
Clin Mol Hepatol. 2012 Sep;18(3):287-94. doi: 10.3350/cmh.2012.18.3.287. Epub 2012 Sep 25.
10
Expression and Significance of Insulin Receptor Substrate 1 in Human Hepatocellular Carcinoma.
Dis Markers. 2020 Jul 10;2020:7174062. doi: 10.1155/2020/7174062. eCollection 2020.

引用本文的文献

2
p53 expression is associated with tumor stage, grade and subtype in patients with hepatocellular carcinoma.
Mol Clin Oncol. 2023 May 24;19(1):54. doi: 10.3892/mco.2023.2650. eCollection 2023 Jul.
4
The expression profiles and prognostic values of HSP70s in hepatocellular carcinoma.
Cancer Cell Int. 2021 May 31;21(1):286. doi: 10.1186/s12935-021-01987-9.
6
Models for Understanding Resistance to Chemotherapy in Liver Cancer.
Cancers (Basel). 2019 Oct 29;11(11):1677. doi: 10.3390/cancers11111677.
8
Increased expression of heat shock protein (HSP) 10 and HSP70 correlates with poor prognosis of nasopharyngeal carcinoma.
Cancer Manag Res. 2019 Sep 6;11:8219-8227. doi: 10.2147/CMAR.S218427. eCollection 2019.
9
Deregulation of miR-34a and Its Chaperon Hsp70 in Hepatitis C virus-Induced Liver Cirrhosis and Hepatocellular Carcinoma Patients.
Asian Pac J Cancer Prev. 2017 Sep 27;18(9):2395-2401. doi: 10.22034/APJCP.2017.18.9.2395.

本文引用的文献

1
Antiviral Therapy of Liver Cirrhosis Related to Hepatitis B Virus Infection.
J Clin Transl Hepatol. 2014 Sep;2(3):197-201. doi: 10.14218/JCTH.2014.00022. Epub 2014 Sep 15.
3
Current and future directions for treating hepatitis B virus infection.
World J Hepatol. 2015 Jun 18;7(11):1541-52. doi: 10.4254/wjh.v7.i11.1541.
4
p53, a translational regulator: contribution to its tumour-suppressor activity.
Oncogene. 2015 Oct 29;34(44):5513-23. doi: 10.1038/onc.2015.25. Epub 2015 Mar 2.
7
Circulating tumor and cancer stem cells in hepatitis C virus-associated liver disease.
World J Gastroenterol. 2014 Dec 28;20(48):18240-8. doi: 10.3748/wjg.v20.i48.18240.
10
MDM2-p53 pathway in hepatocellular carcinoma.
Cancer Res. 2014 Dec 15;74(24):7161-7. doi: 10.1158/0008-5472.CAN-14-1446. Epub 2014 Dec 4.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验